GBS Detection Oligonucleotide Probes and Primers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting Group B Streptococcus (GBS) are slow and inefficient, leading to delayed identification and potential overuse of antibiotics, as culture-based assays take days to produce results, during which transient colonization may occur, necessitating a rapid and accurate DNA-based screening test for effective monitoring and treatment.
Innovation Solution
Development of oligonucleotide probes and primers targeting specific genes (neuA, cspA, cylE, hylB, mreA, and ptsI) for detecting, isolating, amplifying, quantitating, monitoring, screening, and sequencing of GBS, allowing for rapid identification and characterization of GBS in clinical samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If culture-based assays are used to detect GBS, then the detection method is reliable and accurate, but the detection time is prolonged (taking days to produce results)
Solution Approach 1:
The patent replaces the mechanical culture-based detection system with a molecular biology system (PCR and hybridization assays) that detects GBS DNA directly. This substitution eliminates the need for bacterial cultivation while maintaining detection accuracy through specific oligonucleotide probes and primers that target GBS genetic sequences, thereby reducing detection time from days to hours.
Solution Approach 2:
The patent introduces oligonucleotide probes and primers as intermediary molecules that specifically bind to GBS DNA sequences. These intermediaries enable direct detection of GBS genetic material without requiring full bacterial culture, thus maintaining reliability through specific molecular recognition while significantly accelerating the detection process.
2Reliability
If culture-based assays are used to detect GBS, then the detection process is thorough, but the results are delayed allowing transient colonization to occur
Solution Approach 1:
The patent performs preliminary action by directly detecting GBS DNA in clinical samples without waiting for bacterial culture to grow. The PCR amplification and hybridization assays are immediately applicable to extracted DNA, providing rapid results that prevent transient colonization from developing undetected while maintaining thorough detection through specific genetic targeting.
3Productivity
If rapid DNA-based screening is implemented, then the detection speed is improved, but the risk of false positives or reduced accuracy may increase
Solution Approach 1:
The patent applies local quality by designing oligonucleotide probes and primers with highly specific sequences that target unique GBS genetic regions. This localized specificity at the molecular level ensures that rapid DNA-based detection maintains high accuracy by precisely distinguishing GBS DNA from other bacterial DNA, preventing false positives while enabling rapid screening.
Solution Approach 2:
The patent uses oligonucleotide probes and primers as highly specific intermediary molecules that mediate between the DNA sample and detection system. These intermediaries ensure accuracy through complementary base pairing with GBS-specific sequences, allowing rapid detection without sacrificing reliability by filtering out non-specific binding and false signals.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid and accurate detection of GBS, reducing the risk of antibiotic overuse and improving treatment timing by providing immediate insights into GBS colonization status, thereby supporting effective clinical management and preventing antibiotic resistance.
Implementation Method 1
hybridizing one or more isolated nucleic acid sequences comprising a sequence selected from the group consisting of: SEQ ID NOS: 1-35 to a GBS sequence, comprising contacting one or more isolated nucleic acid sequences to a sample comprising the GBS sequence under conditions suitable for hybridization
Implementation Method 2
contacting one or more isolated nucleic acid sequences selected from the group consisting of SEQ ID NOS: 1, 3, 4, 6, 7, 8, 10, 11, 13, 14, 16, 18, 19, 21, 22, 24, 25, 27, 29, 30, 32, 33 and 35 to a sample comprising a GBS sequence under conditions suitable for nucleic acid polymerization
Data Source
AI summary
Described herein are oligonucleotides useful for detecting, isolating, amplifying, quantitating, monitoring, screening and sequencing GBS genes and methods of using the described oligonucleotides.